Faculty of Biomedical & Life Sciences, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK.
Regen Med. 2010 May;5(3):411-23. doi: 10.2217/rme.10.22.
The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.
输注使用捐献的红细胞是一种成熟的细胞疗法。然而,即使在最好的服务中,也存在供应不足、输血传播感染和免疫匹配的需求等问题。通过使用多能干细胞生成通用供体 O 组、RhD 阴性红细胞,可以解决这些问题。人类胚胎干细胞可以无限期地维持和扩增,因此可以产生这种应用所需的大量细胞数。红细胞生成也是多能干细胞衍生治疗的一个有吸引力的目标,因为它是一种特征明确的单细胞悬液,不含有核细胞,且 HLA 分子表达水平低。已经取得了很大的进展;然而,仍有许多挑战需要克服,包括扩大规模、临床效果和产品安全性。